Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Therapy Name | LAG525 |
Synonyms | |
Therapy Description |
LAG525 is a monoclonal antibody that targets LAG3 and blocks interaction with MHC class II molecules, leading to enhanced T-cell response to tumor cells and decreased tumor growth (NCI Drug Dictionary). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
LAG525 | LAG-525|Leramilimab | Immune Checkpoint Inhibitor 98 LAG3 Antibody 12 | LAG525 (Leramilimab) is a monoclonal antibody that targets LAG3 and blocks interaction with MHC class II molecules, leading to enhanced T-cell response to tumor cells and decreased tumor growth (NCI Drug Dictionary). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT03365791 | Phase II | LAG525 Spartalizumab | PDR001 Plus LAG525 for Patients With Advanced Solid and Hematologic Malignancies | Completed | USA | 0 |
NCT02460224 | Phase Ib/II | LAG525 Spartalizumab | Safety and Efficay of LAG525 Single Agent and in Combination With PDR001 in Patients With Advanced Malignancies | Completed | USA | CAN | 10 |